M
Marco Salvetti
Researcher at Sapienza University of Rome
Publications - 294
Citations - 13327
Marco Salvetti is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Multiple sclerosis & Medicine. The author has an hindex of 44, co-authored 263 publications receiving 10931 citations. Previous affiliations of Marco Salvetti include Max Planck Society & Istituto Neurologico Mediterraneo.
Papers
More filters
Journal ArticleDOI
The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study.
Domiziana Rinaldi,Edoardo Bianchini,Michela Sforza,Marika Alborghetti,Silvia Galli,Marco Salvetti,Morena Giovannelli,Francesco E. Pontieri +7 more
TL;DR: Evidence is provided of the efficacy, tolerability and safety of SF in elderly PD patients and there were no significant differences related to age or daily drug dose in tolerability, safety or efficacy.
Journal ArticleDOI
Nerve ultrasonography findings as possible pitfall in differential diagnosis between hereditary transthyretin amyloidosis with polyneuropathy and chronic inflammatory demyelinating polyneuropathy.
Luca Leonardi,Fiammetta Vanoli,Laura Fionda,Simona Loreti,Matteo Garibaldi,Stefania Morino,Marco Salvetti,Domitilla Russo,Beatrice Musumeci,Giovanni Antonini +9 more
TL;DR: It is shown that ATTRv-PN could present the same morphological nerve alterations pattern of CIDP at ultrasonography, adding HRUS findings as a further source of misdiagnosis late-onset ATTRV-PN.
Journal ArticleDOI
Antiviral immune response in patients with multiple sclerosis, healthy siblings and twins.
Giovanni Ristori,Rosella Mechelli,Jourdan Anderson,Fabio Mengoni,Ilaria Sauzullo,Viviana Annibali,Stefania Cannoni,Francesca Aloisi,Judith A. James,Marco Salvetti +9 more
TL;DR: The association between MS status and EBV serology that emerged in some of the tests that have performed should not be overlooked, also considering the lack of substantial genetic, epigenetic and transcriptome variations in identical twins discordant for MS.
Journal ArticleDOI
Drugs used in the treatment of multiple sclerosis during COVID-19 pandemic: a critical viewpoint.
Marika Alborghetti,Gianmarco Bellucci,Antonietta Gentile,Chiara Calderoni,Ferdinando Nicoletti,Ruggero Capra,Marco Salvetti,Diego Centonze +7 more
TL;DR: In this paper, the authors discuss the disease-modifying agents approved for the treatment of multiple sclerosis (MS) within this context and suggest that the use of these agents may not interfere with the development of COVID-19 and may be considered safe.
Journal ArticleDOI
T cell response to N-formylated peptides in humans.
Giovanni Ristori,C. Montesperelli,Maria Teresa Fiorillo,Luca Battistini,Alberto Chersi,Rosa Sorrentino,Giovanna Borsellino,A. Perna,Daniela Tramonti,Stefania Cannoni,Maria Paola Perrone,Franco Giubilei,Paolo Riccio,Marco Salvetti,Carla Buttinelli +14 more
TL;DR: The first evidence of a T lymphocyte response to N‐formylated peptides in humans is presented, which suggests that their expansion in the healthy immune repertoire is independent of the genetic background.